当前位置: 首页 >> 检索结果
1. Quality of Life With Ivabradine in Patients With Angina Pectoris: The Study Assessing the Morbidity-Mortality Benefits of the If Inhibitor Ivabradine in Patients With Coronary Artery Disease Quality of Life Substudy.
作者: Michal Tendera.;Olivier Chassany.;Roberto Ferrari.;Ian Ford.;Philippe Gabriel Steg.;Jean-Claude Tardif.;Kim Fox.; .
来源: Circ Cardiovasc Qual Outcomes. 2016年9卷1期31-8页
To explore the effect of ivabradine on angina-related quality of life (QoL) in patients participating in the Study Assessing the Morbidity-Mortality Benefits of the If Inhibitor Ivabradine in Patients with Coronary Artery Disease (SIGNIFY) QoL substudy.
2. Polypharmacy and the Efficacy and Safety of Rivaroxaban Versus Warfarin in the Prevention of Stroke in Patients With Nonvalvular Atrial Fibrillation.
作者: Jonathan P Piccini.;Anne S Hellkamp.;Jeffrey B Washam.;Richard C Becker.;Günter Breithardt.;Scott D Berkowitz.;Jonathan L Halperin.;Graeme J Hankey.;Werner Hacke.;Kenneth W Mahaffey.;Christopher C Nessel.;Daniel E Singer.;Keith A A Fox.;Manesh R Patel.
来源: Circulation. 2016年133卷4期352-60页
Patients with atrial fibrillation (AF) often take multiple medications.
3. Long-Term Clinical Outcomes of Fractional Flow Reserve-Guided Versus Routine Drug-Eluting Stent Implantation in Patients With Intermediate Coronary Stenosis: Five-Year Clinical Outcomes of DEFER-DES Trial.
作者: Sang Hyun Park.;Ki-Hyun Jeon.;Joo Myung Lee.;Chang-Wook Nam.;Joon-Hyung Doh.;Bong-Ki Lee.;Seung-Woon Rha.;Ki-dong Yoo.;Kyung Tae Jung.;Young-Seok Cho.;Hae-Young Lee.;Tae-Jin Youn.;Woo-Young Chung.;Bon-Kwon Koo.
来源: Circ Cardiovasc Interv. 2015年8卷12期e002442页
We aimed to compare the long-term clinical outcomes between fractional flow reserve (FFR)-guided and routine drug-eluting stent (DES) implantation in patients with an intermediate coronary stenosis.
4. Psychosocial Factors, Exercise Adherence, and Outcomes in Heart Failure Patients: Insights From Heart Failure: A Controlled Trial Investigating Outcomes of Exercise Training (HF-ACTION).
作者: Lauren B Cooper.;Robert J Mentz.;Jie-Lena Sun.;Phillip J Schulte.;Jerome L Fleg.;Lawton S Cooper.;Ileana L Piña.;Eric S Leifer.;William E Kraus.;David J Whellan.;Steven J Keteyian.;Christopher M O'Connor.
来源: Circ Heart Fail. 2015年8卷6期1044-51页
Psychosocial factors may influence adherence with exercise training for heart failure (HF) patients. We aimed to describe the association between social support and barriers to participation with exercise adherence and clinical outcomes.
5. Lifestyle Intervention for Weight Loss and Cardiometabolic Changes in the Setting of Glucokinase Regulatory Protein Inhibition: Glucokinase Regulatory Protein-Leu446Pro Variant in Look AHEAD.
作者: L Maria Belalcazar.;George D Papandonatos.;Bahar Erar.;Inga Peter.;Hadeel Alkofide.;Ashok Balasubramanyam.;Ariel Brautbar.;Steven E Kahn.;William C Knowler.;Christie M Ballantyne.;Jeanne M McCaffery.;Gordon S Huggins.; .
来源: Circ Cardiovasc Genet. 2016年9卷1期71-8页
Glucokinase regulatory protein (GCKR) inhibitors offer a novel treatment approach for glucose control in diabetes mellitus; however, their cardiometabolic effects, particularly in relation to increased triglycerides and C-reactive protein (CRP) levels, are of concern. GCKR Leu446Pro is a common variant associated with reduced GCKR function, increased triglycerides, and CRP.
6. Effects of Ranolazine on Angina and Quality of Life After Percutaneous Coronary Intervention With Incomplete Revascularization: Results From the Ranolazine for Incomplete Vessel Revascularization (RIVER-PCI) Trial.
作者: Karen P Alexander.;Giora Weisz.;Kristi Prather.;Stefan James.;Daniel B Mark.;Kevin J Anstrom.;Linda Davidson-Ray.;Adam Witkowski.;Angel J Mulkay.;Anna Osmukhina.;Ramin Farzaneh-Far.;Ori Ben-Yehuda.;Gregg W Stone.;E Magnus Ohman.
来源: Circulation. 2016年133卷1期39-47页
Angina often persists or returns in populations following percutaneous coronary intervention (PCI). We hypothesized that ranolazine would be effective in reducing angina and improving quality of life (QOL) in incomplete revascularization (ICR) post-PCI patients.
7. Individualized Risk Communication and Outreach for Primary Cardiovascular Disease Prevention in Community Health Centers: Randomized Trial.
作者: Stephen D Persell.;Tiffany Brown.;Ji Young Lee.;Shreya Shah.;Eric Henley.;Timothy Long.;Stephanie Luther.;Donald M Lloyd-Jones.;Muriel Jean-Jacques.;Namratha R Kandula.;Thomas Sanchez.;David W Baker.
来源: Circ Cardiovasc Qual Outcomes. 2015年8卷6期560-6页
Many eligible primary cardiovascular disease prevention candidates are not treated with statins. Electronic health record data can identify patients with increased cardiovascular disease risk.
8. Varenicline for Smoking Cessation in Hospitalized Patients With Acute Coronary Syndrome.
作者: Mark J Eisenberg.;Sarah B Windle.;Nathalie Roy.;Wayne Old.;François R Grondin.;Iqbal Bata.;Ayman Iskander.;Claude Lauzon.;Nalin Srivastava.;Adam Clarke.;Daniel Cassavar.;Danielle Dion.;Herbert Haught.;Shamir R Mehta.;Jean-François Baril.;Charles Lambert.;Mina Madan.;Beth L Abramson.;Payam Dehghani.; .
来源: Circulation. 2016年133卷1期21-30页
Less than one-third of smokers hospitalized with an acute coronary syndrome (ACS) remain abstinent following discharge. We assessed whether varenicline, begun in-hospital, is efficacious for smoking cessation following ACS.
9. Effect of Short-Term Steroid Therapy on Early Recurrence During the Blanking Period After Catheter Ablation of Atrial Fibrillation.
作者: Yoo Ri Kim.;Gi-Byoung Nam.;Seungbong Han.;Sung-Hwan Kim.;Ki-Hun Kim.;Sulhee Lee.;Jun Kim.;Kee-Joon Choi.;You-Ho Kim.
来源: Circ Arrhythm Electrophysiol. 2015年8卷6期1366-72页
Early recurrence (ER) of atrial tachyarrhythmias during the first 3 months (blanking period) after atrial fibrillation ablation can be highly symptomatic, often requiring emergency treatment. Short-term steroid therapy may suppress ER during the blanking period.
10. Identifying Novel Biomarkers for Cardiovascular Events or Death in People With Dysglycemia.
作者: Hertzel C Gerstein.;Guillaume Paré.;Matthew J McQueen.;Heinz Haenel.;Shun Fu Lee.;Janice Pogue.;Aldo P Maggioni.;Salim Yusuf.;Sibylle Hess.; .
来源: Circulation. 2015年132卷24期2297-304页
Serum biomarkers may identify people at risk for cardiovascular (CV) outcomes. Biobanked serum samples from 8494 participants with dysglycemia in the completed Outcome Reduction With Initial Glargine Intervention trial were assayed for 284 biomarkers to identify those that could identify people at risk for a CV outcome or death when added to clinical measurements.
11. Right Atrial Function in Pulmonary Arterial Hypertension.
作者: Gabriela Querejeta Roca.;Patricia Campbell.;Brian Claggett.;Scott D Solomon.;Amil M Shah.
来源: Circ Cardiovasc Imaging. 2015年8卷11期e003521; discussion e003521页
Elevated right atrial (RA) pressure is an established prognostic measure in pulmonary arterial hypertension (PAH). However, little is known about perturbations in RA function in PAH.
12. Relation of Left Ventricular Mass to Prognosis in Initially Asymptomatic Mild to Moderate Aortic Valve Stenosis.
作者: Eva Gerdts.;Anne B Rossebø.;Terje R Pedersen.;Giovanni Cioffi.;Mai Tone Lønnebakken.;Dana Cramariuc.;Barbara P Rogge.;Richard B Devereux.
来源: Circ Cardiovasc Imaging. 2015年8卷11期e003644; discussion e003644页
The prognostic importance of left ventricular (LV) mass in nonsevere asymptomatic aortic stenosis has not been documented in a large prospective study.
13. Long-Term Suppression of Atrial Fibrillation by Botulinum Toxin Injection Into Epicardial Fat Pads in Patients Undergoing Cardiac Surgery: One-Year Follow-Up of a Randomized Pilot Study.
作者: Evgeny Pokushalov.;Boris Kozlov.;Alexander Romanov.;Artem Strelnikov.;Sevda Bayramova.;David Sergeevichev.;Alexander Bogachev-Prokophiev.;Sergey Zheleznev.;Vladimir Shipulin.;Vladimir V Lomivorotov.;Alexander Karaskov.;Sunny S Po.;Jonathan S Steinberg.
来源: Circ Arrhythm Electrophysiol. 2015年8卷6期1334-41页
Animal models suggest that the neurotransmitter inhibitor, botulinum toxin, when injected into the epicardial fat pads can suppress atrial fibrillation inducibility. The aim of this prospective randomized double-blind study was to compare the efficacy and safety of botulinum toxin injection into epicardial fat pads for preventing atrial tachyarrhythmias.
14. Left Ventricular Thrombus Formation After ST-Segment-Elevation Myocardial Infarction: Insights From a Cardiac Magnetic Resonance Multicenter Study.
作者: Janine Pöss.;Steffen Desch.;Charlotte Eitel.;Suzanne de Waha.;Holger Thiele.;Ingo Eitel.
来源: Circ Cardiovasc Imaging. 2015年8卷10期e003417页
Data on left ventricular (LV) thrombus formation after primary percutaneous coronary intervention for ST-segment-elevation myocardial infarction (STEMI) are scarce. The aims of this study were to assess the (1) incidence of LV thrombi using cardiac magnetic resonance in a multicenter cohort of STEMI patients and (2) prognostic relevance of LV thrombi at 1-year follow-up.
15. Prognostic Importance of Changes in Cardiac Structure and Function in Heart Failure With Preserved Ejection Fraction and the Impact of Spironolactone.
作者: Amil M Shah.;Brian Claggett.;Nancy K Sweitzer.;Sanjiv J Shah.;Anita Deswal.;Inder S Anand.;Jerome L Fleg.;Bertram Pitt.;Marc A Pfeffer.;Scott D Solomon.
来源: Circ Heart Fail. 2015年8卷6期1052-8页
Limited data exist regarding the impact of aldosterone antagonist therapy on cardiac structure and function in heart failure with preserved ejection fraction and on the prognostic relevance of changes in cardiac structure and function in heart failure with preserved ejection fraction.
16. Accuracy of Computed Tomographic Angiography and Single-Photon Emission Computed Tomography-Acquired Myocardial Perfusion Imaging for the Diagnosis of Coronary Artery Disease.
作者: Armin Arbab-Zadeh.;Marcelo F Di Carli.;Rodrigo Cerci.;Richard T George.;Marcus Y Chen.;Marc Dewey.;Hiroyuki Niinuma.;Andrea L Vavere.;Aisha Betoko.;Michail Plotkin.;Christopher Cox.;Melvin E Clouse.;Andrew E Arai.;Carlos E Rochitte.;Joao A C Lima.;Jeffrey Brinker.;Julie M Miller.
来源: Circ Cardiovasc Imaging. 2015年8卷10期e003533页
Establishing the diagnosis of coronary artery disease (CAD) in symptomatic patients allows appropriately allocating preventative measures. Single-photon emission computed tomography (CT)-acquired myocardial perfusion imaging (SPECT-MPI) is frequently used for the evaluation of CAD, but coronary CT angiography (CTA) has emerged as a valid alternative.
17. Drug-Coated Balloon Versus Standard Balloon for Superficial Femoral Artery In-Stent Restenosis: The Randomized Femoral Artery In-Stent Restenosis (FAIR) Trial.
作者: Hans Krankenberg.;Thilo Tübler.;Maja Ingwersen.;Michael Schlüter.;Dierk Scheinert.;Erwin Blessing.;Sebastian Sixt.;Arne Kieback.;Ulrich Beschorner.;Thomas Zeller.
来源: Circulation. 2015年132卷23期2230-6页
Drug-coated balloon angioplasty (DCBA) was shown to be superior to standard balloon angioplasty (POBA) in terms of restenosis prevention for de novo superficial femoral artery disease. For in-stent restenosis, the benefit of DCBA over POBA remains uncertain.
18. Final 3-Year Outcome of a Randomized Trial Comparing Second-Generation Drug-Eluting Stents Using Either Biodegradable Polymer or Durable Polymer: NOBORI Biolimus-Eluting Versus XIENCE/PROMUS Everolimus-Eluting Stent Trial.
作者: Masahiro Natsuaki.;Ken Kozuma.;Takeshi Morimoto.;Kazushige Kadota.;Toshiya Muramatsu.;Yoshihisa Nakagawa.;Takashi Akasaka.;Keiichi Igarashi.;Kengo Tanabe.;Yoshihiro Morino.;Tetsuya Ishikawa.;Hideo Nishikawa.;Masaki Awata.;Mitsuru Abe.;Hisayuki Okada.;Yoshiki Takatsu.;Nobuhiko Ogata.;Kazuo Kimura.;Kazushi Urasawa.;Yasuhiro Tarutani.;Nobuo Shiode.;Takeshi Kimura.
来源: Circ Cardiovasc Interv. 2015年8卷10期
There is a paucity of data reporting the clinical outcomes of biodegradable polymer biolimus-eluting stent (BP-BES) compared with durable polymer everolimus-eluting stent (DP-EES) beyond 1 year after stent implantation when the polymer is fully degraded.
19. Statin Use and Adrenal Aldosterone Production in Hypertensive and Diabetic Subjects.
作者: Rene Baudrand.;Luminita H Pojoga.;Anand Vaidya.;Amanda E Garza.;Paul A Vöhringer.;Xavier Jeunemaitre.;Paul N Hopkins.;Tham M Yao.;Jonathan Williams.;Gail K Adler.;Gordon H Williams.
来源: Circulation. 2015年132卷19期1825-33页
Statins substantially reduce cardiovascular mortality and appear to have beneficial effects independent of their lipid-lowering properties. We evaluated the hypothesis that statin use may modulate the secretion of aldosterone, a well-known contributor to cardiovascular disease.
20. Atherogenic Lipoprotein Subfractions Determined by Ion Mobility and First Cardiovascular Events After Random Allocation to High-Intensity Statin or Placebo: The Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) Trial.
作者: Samia Mora.;Michael P Caulfield.;Jay Wohlgemuth.;Zhihong Chen.;H Robert Superko.;Charles M Rowland.;Robert J Glynn.;Paul M Ridker.;Ronald M Krauss.
来源: Circulation. 2015年132卷23期2220-9页
Cardiovascular disease (CVD) can occur in individuals with low low-density lipoprotein (LDL) cholesterol (LDL-C). We investigated whether detailed measures of LDL subfractions and other lipoproteins can be used to assess CVD risk in a population with both low LDL-C and high C-reactive protein who were randomized to high-intensity statin or placebo.
|